These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1008913)

  • 1. Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
    Spöttl F; Froschauer J
    Atherosclerosis; 1976; 25(2-3):293-301. PubMed ID: 1008913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of etofibrate on serum cholesterol and triglycerides (author's transl)].
    Dimroth H
    Med Klin; 1979 Jun; 74(22):875-6. PubMed ID: 470785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in hyperlipidemic rats.
    Priego JG; Maroto ML; Piña M; Catalán RE
    Gen Pharmacol; 1979; 10(4):315-8. PubMed ID: 488666
    [No Abstract]   [Full Text] [Related]  

  • 4. [Etofibrate and clofibrate in a double-blind trial on patients with raised serum-lipid levels (author's transl)].
    Kaffarnik H; Schneider J; Haase W
    Dtsch Med Wochenschr; 1975 Nov; 100(48):2486-8. PubMed ID: 1104303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and hypolipidemic activity of clofibrate-nicotinic acid combinations in rats.
    Cayen MN; Robinson WT; Dubuc J; Dvornik D
    Biochem Pharmacol; 1979 Apr; 28(7):1163-7. PubMed ID: 444274
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
    Schwartzkopff W; Zschiedrich M
    Med Klin; 1978 Feb; 73(7):231-9. PubMed ID: 203832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Field study on the decrease of lipids using etofibrate].
    Schneider J; Haase W; Kaffarnik H
    Fortschr Med; 1976 May; 94(13):785-90. PubMed ID: 8362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
    Sterner W; Schultz A
    Arzneimittelforschung; 1974 Dec; 24(12):1990-2. PubMed ID: 4480360
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P; Schwandt P
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():398-401. PubMed ID: 206058
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinolytic activity and haemagglutination inhibition immunoassays.
    Gormsen J
    Scand J Haematol; 1970; 7(4):261-73. PubMed ID: 4991073
    [No Abstract]   [Full Text] [Related]  

  • 11. Resting levels of blood fibrinolysis in hyperlipoproteinemia.
    Brakman P; Astrup T; Levy RI; Fredrickson DS
    J Appl Physiol; 1974 Apr; 36(4):430-3. PubMed ID: 4274385
    [No Abstract]   [Full Text] [Related]  

  • 12. The mechanism of action of clofibrate and tetranicotinoylfructose (Bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV and type V hypertriglyceridaemia.
    Kissebah AH; Adams PW; Harrigan P; Wynn V
    Eur J Clin Invest; 1974 Jun; 4(3):163-74. PubMed ID: 4838694
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
    Lisch HJ; Patsch J; Sailer S; Braunsteiner H
    Atherosclerosis; 1975; 21(3):391-9. PubMed ID: 1148032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in normolipemic rats.
    Priego JG; Maroto ML; Piña M; Catalan RE
    Gen Pharmacol; 1979; 10(3):215-9. PubMed ID: 467961
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia.
    Patsch JR; Yeshurun D; Jackson RL; Gotto AM
    Am J Med; 1977 Dec; 63(6):1001-9. PubMed ID: 204188
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
    Vessby B; Lithell H; Gustafsson IB; Boberg J
    Atherosclerosis; 1980 Jan; 35(1):51-65. PubMed ID: 6989377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
    Freyberger H; Schifferdecker E; Schatz H
    Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] on lipid metabolism. I. Effect on blood lipids in normal and hyperlipemic rats].
    Maroto ML; Priego JG; Piña M; Catalán RE
    Arch Farmacol Toxicol; 1978 Apr; 4(1):25-7. PubMed ID: 697396
    [No Abstract]   [Full Text] [Related]  

  • 20. [Action of etofibrate, clofibrate and nicotinic acid on the metabolism of lipids in normolipemic rats. Short term effects and method of action].
    Priego JG; Piña M; Armijo M; Sunkel C; Maroto ML
    Arch Farmacol Toxicol; 1979 Apr; 5(1):29-42. PubMed ID: 38756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.